Cargando…

The Coming Age of Flavonoids in the Treatment of Diabetic Complications

Diabetes mellitus (DM), and its micro and macrovascular complications, is one of the biggest challenges for world public health. Despite overall improvement in prevention, diagnosis and treatment, its incidence is expected to continue increasing over the next years. Nowadays, finding therapies to pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Caro-Ordieres, Teresa, Marín-Royo, Gema, Opazo-Ríos, Lucas, Jiménez-Castilla, Luna, Moreno, Juan Antonio, Gómez-Guerrero, Carmen, Egido, Jesús
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7074336/
https://www.ncbi.nlm.nih.gov/pubmed/32012726
http://dx.doi.org/10.3390/jcm9020346
_version_ 1783506810705018880
author Caro-Ordieres, Teresa
Marín-Royo, Gema
Opazo-Ríos, Lucas
Jiménez-Castilla, Luna
Moreno, Juan Antonio
Gómez-Guerrero, Carmen
Egido, Jesús
author_facet Caro-Ordieres, Teresa
Marín-Royo, Gema
Opazo-Ríos, Lucas
Jiménez-Castilla, Luna
Moreno, Juan Antonio
Gómez-Guerrero, Carmen
Egido, Jesús
author_sort Caro-Ordieres, Teresa
collection PubMed
description Diabetes mellitus (DM), and its micro and macrovascular complications, is one of the biggest challenges for world public health. Despite overall improvement in prevention, diagnosis and treatment, its incidence is expected to continue increasing over the next years. Nowadays, finding therapies to prevent or retard the progression of diabetic complications remains an unmet need due to the complexity of mechanisms involved, which include inflammation, oxidative stress and angiogenesis, among others. Flavonoids are natural antioxidant compounds that have been shown to possess anti-diabetic properties. Moreover, increasing scientific evidence has demonstrated their potential anti-inflammatory and anti-oxidant effects. Consequently, the use of these compounds as anti-diabetic drugs has generated growing interest, as is reflected in the numerous in vitro and in vivo studies related to this field. Therefore, the aim of this review is to assess the recent pre-clinical and clinical research about the potential effect of flavonoids in the amelioration of diabetic complications. In brief, we provide updated information concerning the discrepancy between the numerous experimental studies supporting the efficacy of flavonoids on diabetic complications and the lack of appropriate and well-designed clinical trials. Due to the well-described beneficial effects on different mechanisms involved in diabetic complications, the excellent tolerability and low cost, future randomized controlled studies with compounds that have adequate bioavailability should be evaluated as add-on therapy on well-established anti-diabetic drugs.
format Online
Article
Text
id pubmed-7074336
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-70743362020-03-20 The Coming Age of Flavonoids in the Treatment of Diabetic Complications Caro-Ordieres, Teresa Marín-Royo, Gema Opazo-Ríos, Lucas Jiménez-Castilla, Luna Moreno, Juan Antonio Gómez-Guerrero, Carmen Egido, Jesús J Clin Med Review Diabetes mellitus (DM), and its micro and macrovascular complications, is one of the biggest challenges for world public health. Despite overall improvement in prevention, diagnosis and treatment, its incidence is expected to continue increasing over the next years. Nowadays, finding therapies to prevent or retard the progression of diabetic complications remains an unmet need due to the complexity of mechanisms involved, which include inflammation, oxidative stress and angiogenesis, among others. Flavonoids are natural antioxidant compounds that have been shown to possess anti-diabetic properties. Moreover, increasing scientific evidence has demonstrated their potential anti-inflammatory and anti-oxidant effects. Consequently, the use of these compounds as anti-diabetic drugs has generated growing interest, as is reflected in the numerous in vitro and in vivo studies related to this field. Therefore, the aim of this review is to assess the recent pre-clinical and clinical research about the potential effect of flavonoids in the amelioration of diabetic complications. In brief, we provide updated information concerning the discrepancy between the numerous experimental studies supporting the efficacy of flavonoids on diabetic complications and the lack of appropriate and well-designed clinical trials. Due to the well-described beneficial effects on different mechanisms involved in diabetic complications, the excellent tolerability and low cost, future randomized controlled studies with compounds that have adequate bioavailability should be evaluated as add-on therapy on well-established anti-diabetic drugs. MDPI 2020-01-27 /pmc/articles/PMC7074336/ /pubmed/32012726 http://dx.doi.org/10.3390/jcm9020346 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Caro-Ordieres, Teresa
Marín-Royo, Gema
Opazo-Ríos, Lucas
Jiménez-Castilla, Luna
Moreno, Juan Antonio
Gómez-Guerrero, Carmen
Egido, Jesús
The Coming Age of Flavonoids in the Treatment of Diabetic Complications
title The Coming Age of Flavonoids in the Treatment of Diabetic Complications
title_full The Coming Age of Flavonoids in the Treatment of Diabetic Complications
title_fullStr The Coming Age of Flavonoids in the Treatment of Diabetic Complications
title_full_unstemmed The Coming Age of Flavonoids in the Treatment of Diabetic Complications
title_short The Coming Age of Flavonoids in the Treatment of Diabetic Complications
title_sort coming age of flavonoids in the treatment of diabetic complications
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7074336/
https://www.ncbi.nlm.nih.gov/pubmed/32012726
http://dx.doi.org/10.3390/jcm9020346
work_keys_str_mv AT caroordieresteresa thecomingageofflavonoidsinthetreatmentofdiabeticcomplications
AT marinroyogema thecomingageofflavonoidsinthetreatmentofdiabeticcomplications
AT opazorioslucas thecomingageofflavonoidsinthetreatmentofdiabeticcomplications
AT jimenezcastillaluna thecomingageofflavonoidsinthetreatmentofdiabeticcomplications
AT morenojuanantonio thecomingageofflavonoidsinthetreatmentofdiabeticcomplications
AT gomezguerrerocarmen thecomingageofflavonoidsinthetreatmentofdiabeticcomplications
AT egidojesus thecomingageofflavonoidsinthetreatmentofdiabeticcomplications
AT caroordieresteresa comingageofflavonoidsinthetreatmentofdiabeticcomplications
AT marinroyogema comingageofflavonoidsinthetreatmentofdiabeticcomplications
AT opazorioslucas comingageofflavonoidsinthetreatmentofdiabeticcomplications
AT jimenezcastillaluna comingageofflavonoidsinthetreatmentofdiabeticcomplications
AT morenojuanantonio comingageofflavonoidsinthetreatmentofdiabeticcomplications
AT gomezguerrerocarmen comingageofflavonoidsinthetreatmentofdiabeticcomplications
AT egidojesus comingageofflavonoidsinthetreatmentofdiabeticcomplications